A recently registered clinical trial with Vorinostat included a combination treatment with Pembrolizumab (anti-PD-1 mAb), TMZ, and RT for newly diagnosed GBM patients (NCT03426891). This evidence concerns the gene PDCD1 and glioblastoma.